

BSW Formulary Update – Following APC Apr 2021 meeting

New and Updated Prescribing Guidelines

- **Updated** - [BSW Management of Infection Guidance for Primary Care](#). Update incorporates NICE guidance [NG190](#) on secondary bacterial infection of eczema and other common skin conditions. The section on bacterial conjunctivitis has been revised to include updated information on prescribing chloramphenicol eye products in children <2yrs; Chloramphenicol eye **drops** are no longer licensed in age <2s. Chloramphenicol eye **ointment** (off-label use) is considered first line in this age group as per local acute trust guidance. See formulary entry [here](#) and also see this [SPS summary of using chloramphenicol eye products in <2yrs](#). The section on threadworm includes updated wording that the use of mebendazole in age under 2 is off-label in line with revised product SPC.
- **New** - [BSW SCA Midodrine \(licensed\) &/or Fludrocortisone \(off-label\) for orthostatic hypotension – Adults](#). This SCA is new for most prescribing across BSW but note it replaces expired SCA for midodrine previously used at SFT).
- **New** - [Guidelines for the use of Dapagliflozin \(a SGLT2\) in Heart Failure \(HF\)](#) in line with [NICE TA679](#). Locally developed guidance supports primary care to take on prescribing of [dapagliflozin for HF \(Amber TLS indication\)](#). There are important nuances for using in HF as opposed to diabetes which we are all more familiar with. Clinicians should be aware of this guideline and implement any necessary changes to their practice. The indication for dapagliflozin must be clearly documented on the patient's medical record.
- **New** – [Guidelines for the use of melatonin in children for Autism Spectrum Disorder \(ASD\)](#). This BSW guideline aims to:

 1. Highlight the current evidence base and areas where the evidence for using melatonin is lacking.
 2. Raise awareness of theoretical risks of puberty delay, safety concerns about use in pregnancy and longer term safety in general noting ongoing studies into these areas.
 3. Advise on the 'transition' of patients out of paediatric services at age 18 years. **There is a change in TLS from RED to Amber to accommodate prescribing of melatonin in those >18years where a recent drug review by the paediatric service has shown there is a continued need for the GP to continue to prescribe melatonin as per this local guidance.** See formulary entry [here](#)

New additions to the BSWformulary

- [Vedolizumab 108 mg solution for injection](#) in PFS for SC injection added as an alternative to IV for patients who fulfil NICE criteria (and BSW Gastro pathways). **Red TLS**

TLS Aligned for BSW

- [Mydrane® solution for intracameral injection](#) aligned for use by specialist teams across BSW. **Red TLS**

What the BSW CCG formulary team are currently working on

- Working to improve the understanding of the definition of the Traffic Light System and initiation of shared care prescribing, to improve engagement and adherence to the BSWformulary across primary and secondary care.
- Working on building and improving the Paediatric formulary chapter.
- Reviewing formulary position of Cox-2 inhibitors.
- Prescribing guidance on primary care management of chronic urticarial.
- Updating COPD guidance and considering formulary position of new triple inhalers.
- Reviewing formulary application for Ferric maltol (Ferracru) and proposed pathway for its use.
- Working with AWP on an oral antipsychotic SCA.
- Updating the HRT pathway and reviewing the BSWCCG policy for use of Testosterone in HRT.
- Reviewing the BSWCCG policy on continuous glucose monitoring.
- Updating the BSW primary care antibiotic guidance in line with NICE updates and reviewing TLS and primary care prescribing of rifampicin.

The BSW joint formulary remains under construction and is designed to be an evolving, dynamic resource. We are working to ensure the messages on GP prescribing systems are in line with the joint formulary. If you discover information you believe to be inaccurate or misleading, or for further information, email bswccg.formulary@nhs.net

